ReviewInfectious disease clinics of North America2008
Chronic Lyme disease: a review.
Review in Infectious disease clinics of North America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 225 citations in OpenAlex.
- Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis.BMC infectious diseases · 2023Pooled it
- Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study.BMC infectious diseases · 2012Trial
- Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.Brain : a journal of neurology · 2026Review
- Pilot study of psilocybin in patients with post-treatment lyme disease.Scientific reports · 2026Article
- Emerging risk of tick-borne diseases in South Korea: Lyme disease, anaplasmosis, and babesiosis.Clinical and experimental vaccine research · 2026Review
- Patient roadmap and economic burden of chronic tick-borne illness and post-treatment Lyme disease syndrome in Ireland, and public health issues arising.Frontiers in public health · 2026Article
- Probable European-profileFrontiers in medicine · 2026Article
- Targeting of interaction between BB0323-BB0238 informs new paradigms in Lyme disease therapeutics.PLoS pathogens · 2026Article
- Early brain changes in Lyme disease are associated with clinical outcomes.Brain, behavior, & immunity - health · 2025Article
- Misdiagnosed Lyme: A Multidisciplinary Case Series from a Non-Endemic RegionBalkan medical journal · 2025Article
- Lyme Disease Biobank: 10 years of 3 month follow-up visits from 2014 to 2023.Frontiers in medicine · 2025Article
- Proposed research classification criteria for Lyme disease in infection associated chronic illness studies.Frontiers in medicine · 2025Article
- Biomarker-Based Analysis of Pain in Patients with Tick-Borne Infections before and after Antibiotic Treatment.Antibiotics (Basel, Switzerland) · 2024Article
- Spatiotemporal patterns of Lyme disease in North Carolina: 2010-2020.Lancet regional health. Americas · 2024Article
- Article
- Suppression of host humoral immunity byInfection and immunity · 2024Article
- Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2024Article
- Antigenicity and immunogenicity of different morphological forms of Borrelia burgdorferi sensu lato spirochetes.Scientific reports · 2024Article
- Current and emerging approaches for eliminatingFrontiers in microbiology · 2024Review
- Unguarded liabilities:Frontiers in antibiotics · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Studies have shown that most patients diagnosed with chronic Lyme disease either have no objective evidence of previous or current infection with Borrelia burgdorferi or are patients who should be classified as having post-Lyme disease syndrome, which is defined as continuing or relapsing nonspecific symptoms (such as fatigue, musculoskeletal pain, and cognitive complaints) in a patient previously treated for Lyme disease. Despite extensive study, there is currently no clear evidence that post-Lyme disease syndrome is caused by persistent infection with B burgdorferi. Four randomized placebo-controlled studies have shown that antibiotic therapy offers no sustained benefit to patients who have post-Lyme disease syndrome. These studies also showed a substantial placebo effect and a significant risk of treatment-related adverse events. Further research to elucidate the mechanisms underlying persistent symptoms after Lyme disease and controlled trials of new approaches to the treatment and management of these patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.